27 results
DEF 14A
IMCR
Immunocore Holdings plc
12 Apr 24
Definitive proxy
4:20pm
listed below have sole voting and investment power with respect to the shares beneficially owned by them, subject to applicable community property laws
424B7
IMCR
Immunocore Holdings plc
5 Apr 24
Prospectus with selling stockholder info
4:34pm
product candidates among physicians, patients, patient advocacy groups, third-party payors and the medical community and our ability and our … acceptance of our product candidates among physicians, patients, patient advocacy groups, third-party payors and the medical community and our ability
PRE 14A
IMCR
Immunocore Holdings plc
2 Apr 24
Preliminary proxy
4:45pm
listed below have sole voting and investment power with respect to the shares beneficially owned by them, subject to applicable community property laws
S-3ASR
IMCR
Immunocore Holdings plc
20 Mar 24
Automatic shelf registration
8:51pm
acceptance of our product candidates among physicians, patients, patient advocacy groups, third-party payors and the medical community and our ability … relationships with suppliers, customers and others, (iv) the impact of the company’s operations on the community and the environment, (v
8-K
EX-99.2
IMCR
Immunocore Holdings plc
28 Feb 24
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
4:19pm
and delivering transformative immunomodulating medicines
$238.7M FY23 net sales with 3 Additional Growth Opportunities US Community & global expansion
10-K
ssagone
28 Feb 24
Annual report
7:33am
6-K
EX-99.4
gn4 2h3cja
10 Aug 23
Current report (foreign)
8:28am
6-K
EX-99.3
9e1e41s2s8
10 May 23
Current report (foreign)
7:27am
6-K
EX-99.3
xr264gn4pfnjkfi4
9 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:15am
6-K
EX-99.4
0i6hx 631y3b
9 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:15am
424B7
sniummqj6
30 Sep 22
Prospectus with selling stockholder info
4:15pm
424B5
962ugiujxb
9 Sep 22
Prospectus supplement for primary offering
4:23pm
6-K
EX-99.4
k3x0bnkhdu
10 Aug 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
8:00am
6-K
EX-99.1
9wh48
8 Jun 22
KIMMTRAK is the first and only treatment approved in the UK, Australia, and Canada to treat patients with unresectable or metastatic uveal melanoma
4:06pm
424B7
w2zg78nagw
5 May 22
Prospectus with selling stockholder info
12:00am
F-3ASR
w6zlv jzt
4 Apr 22
Automatic shelf registration (foreign)
4:08pm
20-F
1g1 oepmp3ji7jer4jc
25 Mar 21
Annual report (foreign)
7:01am
20-F
EX-2.4
76h2yow pofl
25 Mar 21
Annual report (foreign)
7:01am
424B4
aogxysu 4wmdinn
8 Feb 21
Prospectus supplement with pricing info
8:36am